- Home
- NGNE vs BGH Comparison
NGNE vs BGH Comparison
Compare NGNE & BGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- BGH
- Stock Information
- Founded
- NGNE 2003
- BGH 2012
- Country
- NGNE United States
- BGH United States
- Employees
- NGNE N/A
- BGH N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- BGH Investment Managers
- Sector
- NGNE Health Care
- BGH Finance
- Exchange
- NGNE Nasdaq
- BGH Nasdaq
- Market Cap
- NGNE 325.3M
- BGH 318.8M
- IPO Year
- NGNE N/A
- BGH N/A
- Fundamental
- Price
- NGNE $18.48
- BGH $16.37
- Analyst Decision
- NGNE Strong Buy
- BGH
- Analyst Count
- NGNE 7
- BGH 0
- Target Price
- NGNE $41.86
- BGH N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- BGH 61.5K
- Earning Date
- NGNE 08-11-2025
- BGH 01-01-0001
- Dividend Yield
- NGNE N/A
- BGH 10.06%
- EPS Growth
- NGNE N/A
- BGH N/A
- EPS
- NGNE N/A
- BGH N/A
- Revenue
- NGNE N/A
- BGH N/A
- Revenue This Year
- NGNE N/A
- BGH N/A
- Revenue Next Year
- NGNE N/A
- BGH N/A
- P/E Ratio
- NGNE N/A
- BGH N/A
- Revenue Growth
- NGNE N/A
- BGH N/A
- 52 Week Low
- NGNE $6.88
- BGH $11.92
- 52 Week High
- NGNE $74.49
- BGH $14.50
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- BGH 63.33
- Support Level
- NGNE $19.59
- BGH $15.76
- Resistance Level
- NGNE $20.46
- BGH $16.43
- Average True Range (ATR)
- NGNE 1.23
- BGH 0.14
- MACD
- NGNE -0.20
- BGH -0.00
- Stochastic Oscillator
- NGNE 13.37
- BGH 91.04
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.